Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVXL NYSE:GLAS NASDAQ:IVA NASDAQ:REPL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$2.50+2.7%$2.73$2.30▼$13.99$230.29M1.141.37 million shs570,173 shsGLASGlass House Brands$10.85-5.0%$0.00$4.95▼$13.93$872.56MN/A245,225 shs313,687 shsIVAInventiva$4.45+1.0%$4.41$2.85▼$7.98$921.19M0.72645,422 shs887,263 shsREPLReplimune Group$9.75-1.2%$8.31$1.50▼$13.24$819.72M0.864.53 million shs1.14 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences+3.40%-10.33%-2.80%-25.00%-78.83%GLASGlass House Brands-0.88%-1.29%+1,134,999,900.00%+1,134,999,900.00%+1,134,999,900.00%IVAInventiva+2.33%-3.51%+14.29%-23.34%+27.17%REPLReplimune Group-0.70%-14.25%+11.15%+332.89%-12.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$2.50+2.7%$2.73$2.30▼$13.99$230.29M1.141.37 million shs570,173 shsGLASGlass House Brands$10.85-5.0%$0.00$4.95▼$13.93$872.56MN/A245,225 shs313,687 shsIVAInventiva$4.45+1.0%$4.41$2.85▼$7.98$921.19M0.72645,422 shs887,263 shsREPLReplimune Group$9.75-1.2%$8.31$1.50▼$13.24$819.72M0.864.53 million shs1.14 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences+3.40%-10.33%-2.80%-25.00%-78.83%GLASGlass House Brands-0.88%-1.29%+1,134,999,900.00%+1,134,999,900.00%+1,134,999,900.00%IVAInventiva+2.33%-3.51%+14.29%-23.34%+27.17%REPLReplimune Group-0.70%-14.25%+11.15%+332.89%-12.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVXLAnavex Life Sciences 2.40Hold$21.33755.04% UpsideGLASGlass House Brands 2.67Moderate Buy$17.0056.68% UpsideIVAInventiva 3.10Buy$16.56272.45% UpsideREPLReplimune Group 2.00Hold$8.13-16.69% DownsideCurrent Analyst Ratings BreakdownLatest AVXL, REPL, GLAS, and IVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/13/2026GLASGlass House Brands Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$17.007/2/2026REPLReplimune Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/1/2026GLASGlass House Brands Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell (D+)6/30/2026GLASGlass House Brands Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/30/2026REPLReplimune Group BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderperform ➝ Outperform$16.006/30/2026REPLReplimune Group WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$6.00 ➝ $9.006/26/2026REPLReplimune Group JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Overweight$17.006/18/2026REPLReplimune Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/11/2026AVXLAnavex Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/3/2026REPLReplimune Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/1/2026REPLReplimune Group WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$2.00 ➝ $6.00(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVXLAnavex Life SciencesN/AN/AN/AN/A$1.10 per shareN/AGLASGlass House Brands$176.02M4.95N/AN/AN/A∞IVAInventiva$5.07M182.10N/AN/A($0.22) per share-20.20REPLReplimune GroupN/AN/AN/AN/A$2.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVXLAnavex Life Sciences-$46.38M-$0.46N/AN/AN/AN/A-38.76%-35.01%7/16/2026 (Estimated)GLASGlass House BrandsN/AN/AN/AN/AN/AN/AN/AN/AN/AIVAInventiva-$400.67MN/AN/AN/AN/AN/AN/AN/A9/25/2026 (Estimated)REPLReplimune Group-$313.94M-$3.38N/AN/AN/AN/A-128.57%-82.35%8/6/2026 (Estimated)Latest AVXL, REPL, GLAS, and IVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026AVXLAnavex Life Sciences-$0.08N/AN/AN/AN/AN/A8/6/2026Q1 2027REPLReplimune Group-$0.64N/AN/AN/A$13.60 millionN/A7/16/2026Q2 2026AVXLAnavex Life Sciences-$0.07N/AN/AN/AN/AN/A6/29/2026Q4 2026REPLReplimune Group-$0.6613-$0.76-$0.0988-$0.76$3.57 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVXLAnavex Life SciencesN/AN/AN/AN/AN/AGLASGlass House BrandsN/AN/AN/AN/AN/AIVAInventivaN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVXLAnavex Life SciencesN/A20.8720.87GLASGlass House BrandsN/AN/AN/AIVAInventivaN/A3.163.16REPLReplimune Group0.634.794.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVXLAnavex Life Sciences31.55%GLASGlass House BrandsN/AIVAInventiva19.06%REPLReplimune Group92.53%Insider OwnershipCompanyInsider OwnershipAVXLAnavex Life Sciences11.40%GLASGlass House BrandsN/AIVAInventiva32.00%REPLReplimune Group5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVXLAnavex Life Sciences4092.67 million82.48 millionOptionableGLASGlass House BrandsN/A80.27 millionN/AN/AIVAInventiva100207.71 million141.24 millionNot OptionableREPLReplimune Group21083.95 million79.58 millionOptionableAVXL, REPL, GLAS, and IVA HeadlinesRecent News About These CompaniesJohnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Replimune Group, Inc. (REPL)4 hours ago | globenewswire.comCandriam S.C.A. Buys Shares of 394,027 Replimune Group, Inc. $REPLJuly 15 at 3:43 AM | marketbeat.comTraders Purchase Large Volume of Replimune Group Put Options (NASDAQ:REPL)July 13 at 5:59 PM | marketbeat.comReplimune Group (NASDAQ:REPL) Shares Down 6.6% - What's Next?July 13 at 11:59 AM | marketbeat.comReplimune Group, Inc. Common Stock (REPL)July 8, 2026 | nasdaq.comReplimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of "Hold" by AnalystsJuly 5, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Replimune Group (REPL), Abivax SA Sponsored ADR (ABVX) and Larimar Therapeutics (LRMR)July 1, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Replimune Group (REPL) and Monopar Therapeutics Inc (MNPR)June 30, 2026 | theglobeandmail.comReplimune: Stock Buoyant On Third Try At RP1 Approval - FDA AdCom May Be CrucialJune 30, 2026 | seekingalpha.comReplimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate UpdateJune 29, 2026 | globenewswire.comReplimune’s RP1 BLA Resubmission Accepted for ReviewJune 28, 2026 | theglobeandmail.comReplimune Group Announces FDA Acceptance for Review of RP1 BLA Resubmission in Advanced MelanomaJune 26, 2026 | quiverquant.comQReplimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced MelanomaJune 26, 2026 | globenewswire.comReplimune: Modeling The Coin Flip Of FDA ApprovalJune 4, 2026 | seekingalpha.comInsider Selling: Replimune Group (NASDAQ:REPL) Insider Sells 12,000 Shares of StockJune 4, 2026 | insidertrades.comReplimune Group, Inc.: Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology ...June 1, 2026 | finanznachrichten.deReplimune Group, Inc.: Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical ...June 1, 2026 | finanznachrichten.deWhy Is REPL Stock Gaining In Pre-Market Today?June 1, 2026 | finance.yahoo.comREPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo DrugJune 1, 2026 | zacks.comReplimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral ...May 31, 2026 | caledonianrecord.comCReplimune Group Presents Final First-in-Human Data for RP2 Oncolytic Immunotherapy at ASCO 2026May 31, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesGravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026The Oil Trade May Not Be Over: 3 Energy Stocks to WatchBy Thomas Hughes | June 21, 2026Could a Tesla-SpaceX Merger Be Closer Than Investors Think?By Sam Quirke | June 17, 2026Starbucks Builds Sovereign AI to Cut $400 Million in Software CostsBy Jeffrey Neal Johnson | July 11, 2026AVXL, REPL, GLAS, and IVA Company DescriptionsAnavex Life Sciences NASDAQ:AVXL$2.50 +0.07 (+2.67%) As of 03:56 PM Eastern This is a fair market value price provided by Massive. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Glass House Brands NYSE:GLAS$10.85 -0.57 (-4.99%) As of 03:56 PM Eastern This is a fair market value price provided by Massive. Learn more.Inventiva NASDAQ:IVA$4.44 +0.05 (+1.02%) As of 03:56 PM Eastern This is a fair market value price provided by Massive. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Replimune Group NASDAQ:REPL$9.75 -0.12 (-1.19%) As of 03:56 PM Eastern This is a fair market value price provided by Massive. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings Why ASML’s AI Monopoly Is Still Getting Stronger Alphabet’s AI Spending Question Looms Over Q2 Earnings CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks 2 Quantum Stocks That Could Challenge IonQ’s Leadership 3 Small-Cap Stocks Trading Under $10 With Room to Run Plot Twist: 12 States Could Stall the Paramount-Warner Bros. Discovery Mega-Merger Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
